An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Launched by WUHAN UNION HOSPITAL, CHINA · Apr 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called hetrombopag in patients with two specific blood disorders: Immune Thrombocytopenia (ITP) and Aplastic Anemia (AA). The goal is to gather information on how well hetrombopag works in real-life situations and how it is used by doctors in their everyday practice. This is not a clinical trial where patients are being treated differently; instead, participants will receive hetrombopag as part of their normal medical care.

To be eligible for this study, patients must have a confirmed diagnosis of ITP and be prescribed hetrombopag by their doctor. It’s important that the decision to start this medication is made by the treating physician, independent of the study. Patients will need to provide their consent to participate and be willing to follow the study's requirements. This trial is not currently recruiting participants, but it aims to help improve our understanding of how hetrombopag works for patients with these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.Established and well documented ITP diagnosis
• • 2.Patient is treated with, or at enrollment prescribed hetrombopag for ITP. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study.
• • 3.Signed and dated informed consent provided by the patient before any study-related activities are undertaken
• • 4.Willing and able to comply with protocol requirements
• Exclusion Criteria:
• • Enrollment in a concurrent clinical interventional study